login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Refined balloon pulmonary angioplasty procedure improves the clinical status of CTEPH patients


Friday, 21 Dec 2012 11:37
Hiromi Matsubara
Hiromi Matsubara

Hiroki Mizoguchi, Division of Cardiology, National Hospital Organization Okayama Medical Center, Okayama, Japan, and colleagues have refined balloon pulmonary angioplasty for the treatment of inoperable patients with chronic thromboemobolic pulmonary hypertension (CTEPH).


The study leader Hiromi Matsubara, Department of Clinical Science, National Hospital Organization Okayama Medical Center, Okayama, Japan, commented on the study and said: “Recent progress in medical treatment for pulmonary arterial hypertension has improved the prognosis of the patients with the problem. However, patients with CTEPH have been left behind this progress. There have been no effective therapeutic options, especially for the patients diagnosed as unsuitable for pulmonary endarterectomy.”

Balloon pulmonary angioplasty for the treatment of CTEPH was first reported over 10 years ago therefore the authors aimed to readdress the procedure to maximise its clinical efficacy.

In the study, 68 patients with inoperable CTEPH were enrolled and underwent balloon pulmonary angioplasty. The patients were diagnosed as inoperable because of the location of the thrombi and surgical accessibility, age and comorbidities. All patients were in the World Health Organisation (WHO) functional class III or IV with high pulmonary arterial pressure.

Balloon pulmonary angioplasty procedure

According to the study, 68 patients underwent a total of 255 balloon pulmonary angioplasty sessions in which four (2–8) sessions were performed in each patient and the number of vessels dilated per session was three (1–14). The result of the balloon pulmonary angioplasty sessions was that one patient died after the third session because of right-sided heart failure and of the remaining 67 patients 64 (96%) were in the WHO functional class of I or II after the final session. Overall the mean pulmonary arterial pressure was significantly reduced (p<0.01) according to Mizoguchi and others.

Patients were followed up every six months after balloon pulmonary angioplasty. During follow-up one patient died of pneumonia and the remaining 66 patients are alive with 57 patients undergoing right heart catheterisation after final balloon pulmonary angioplasty. The authors reported that these patients had mean pulmonary arterial pressure of 24.0±5.8mmHg with maintained improved heamodynamics at 1±0.9 years.

The implications of the refined balloon pulmonary angioplasty as a treatment for inoperable CTEPH is that it adds to the weight of evidence which suggests it is an effective therapeutic option.

“With the refined technique, we could maximise the efficacy of balloon pulmonary angioplasty for inoperable patients with CTEPH without increasing complications. Improvements of haemodynamics and clinical function obtained by angioplasty were maintained for at least one year. Overall the outcome of angioplasty was almost comparable to that of endarterectomy,” said Matsubara. “Although there are remaining problems to be resolved such as the risk of reperfusion injury and the existence of a learning curve in performing the procedure, our results open up the prospect of pulmonary angioplasty as a promising therapeutic option for patients with CTEPH,” he added.

“Our refined balloon pulmonary angioplasty procedure improves clinical status and the haemodynamic of inoperable patients with CTEPH, with a low mortality,” concluded Mizoguchi et al.




Add New Comment

Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha
Tuesday, 08 Jul 2014
The 11th Scientific Meeting of the Chinese Society of Interventional Radiology (2014 CSIR) was held from 11–15 June 2014 in Changsha, Hunan Province, China. The Chinese Society of Interventional R... The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha

Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy
Tuesday, 08 Jul 2014
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or ... Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions